Q3 Revenue Jumps 13% to $717M, but Q4 Guidance Calls for 10-12% Decline
AMN has more than doubled off its 52-week low of $14.97.
Summary
Q3 revenue came in at $717M, up 13% year over year and 7% from Q2's $673M, with adjusted diluted EPS of $1.16 versus $0.39 a year earlier. Adjusted EBITDA rose 63% to $94M, a 13.0% margin, helped by a reserve release that lifted gross margin sequentially. The catch is the forward view: management guides Q4 revenue down 10-12% year over year, assuming only $5M of labor disruption revenue versus $124M in Q4 2025 — the comparison period is doing much of the work in both directions. Q3 also burned $88M of operating cash as the company refunded most client deposits tied to prior labor disruption events, a real cash drag behind the headline growth. Q4 results will show whether the underlying business holds up once the labor disruption tailwind is gone.
At the time of this announcement, AMN was trading at $49.05 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $14.97 to $49.62. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Wiseek News.